Competence Centre on Health Technologies
+372 733 0403
[email protected]
Follow us on

FAQ

Practical notes of beREADY test

beREADY test needs a small tissue sample from your uterus and related clinical data. Your doctor takes the tissue sample using a thin catheter, places the sample into transportation solution and ships it to beREADY laboratory
Tissue sampling procedure does not injure the uterus. The tissue regenerates in the next menstrual cycle and stays healthy
The test is validated for natural (LH) and hormone replacement therapy cycle (HRT)
Please note that embryo transfer at the same menstrual cycle as beREADY test has taken, is not possible
Image link
Handling of personal data
All your personal data is protected according to law. Sample related information is transferred to the laboratory via a highly secure digital environment. The test results are uploaded to a secure online environment and your doctor has access to it. You may request the doctor for a printed copy of the beREADY report. The report includes all relevant treatment and tissue sampling information.

General questions about beREADY test

Does the beREADY test guarantee a pregnancy? 
Possible failure of embryo implantation can be caused by other reasons like embryo quality and etc. Thus, beREADY test cannot guarantee you pregnancy. But it does give your doctor a guidance of how to personalise your IFV treatment. If you have displaced WOI, the beREADY increases your chances of getting pregnant. Our experience shows that many women (56%) with previous implantation failure become pregnant after using beREADY test.
What kind of sample is needed for the test?
beREADY test needs a small endometrial tissue sample for analysis. The tissue sample is taken from the uterus with a thin catheter. Tissue sampling procedure does not injure the uterus and the tissue is fully regenerated in the next menstrual cycle.
Does re-sampling cost?
beREADY test report may recommend a re-biopsy to confirm that the optimal WOI is achieved. To be sure that your personalised treatment plan is effective, one repetition is free-of-charge.
How quickly do I receive results?
We send your test results to your doctor within 14 working days after recieving your sample. Our average laboratory turnaround time is 6-8 working days. Embryo transfer at the same menstrual cycle as taking the beREADY test, is not possible.
My personal WOI is significantly shifted. What next?
Your doctor will adjust your treatment plan according to beREADY results. We may recommend to take a new tissue sample only if your WOI is significantly shifted and our suggested timing needs approval. Our recommended re-biopsy analysis is free of charge.
What are the marker genes that beREADY test analyses? 
Through laboratory and computational analyses, the beREADY test evaluates the gene expression level of 67 genes. All the genes are involved in endometrial growth, maturation and receptivity. These genes characterise the readiness of tested endometrium for embryo implantation. Our research has determined that analysed 67 genes are sufficient and highly accurate for receptivity testing. Including more genes does not make the test better.
Image link
I don’t see a clinic near my home? Where can I take the test?
If you wish to perform the beREADY test but your clinic is not here, please let us know. We will find the closest available location for your test or try to create a partnership with your clinic.
How is my personal health data protected?
All your personal data is protected according to law and transferred to laboratory via a secure website. The test results are uploaded to a secure website that your doctor can access. The patient may request the doctor for a printed copy of the beREADY report, which includes all relevant treatment and tissue sampling information.
What is the scientific evidence behind the beREADY test?

Our researchers have published several peer-revewed articles. The articles demonstrate the technology behind beREADY analysis, selection of the biomarkers and data analysis:

 

Saare et al., A molecular tool for menstrual cycle phase dating in endometriosis transcriptomic studies. 2019, Biology of Reproduction, PubMed ID 31004479. Link to original study

 

Teder et al., TAC-seq: targeted DNA and RNA sequencing for precise biomarker molecule counting. 2018, npj Genomic Medicine, PubMed ID 30588329. Link to original study

 

Suhorutshenko et al., Endometrial receptivity revisited: endometrial transcriptome adjusted for tissue cellular heterogeneity. 2018, Human Reproduction, PubMed ID 30295736. Link to original study

 

Altmäe et al., Meta-signature of human endometrial receptivity: a meta-analysis and validation study of transcriptomic biomarkers. 2017, Scientific Reports, PubMed ID 28855728. Link to original study

 

Krjutškov et al., Single-cell transcriptome analysis of endometrial tissue. 2016, Human Reproduction, PubMed ID 26874359. Link to original study